Study Title

PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

Study Details

Description:

Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine which patients are likely to respond to targeted HER2 agents as single agent therapy. We are proposing to perform a pilot study with goals of demonstrating the feasibility of imaging breast cancer patients with 89Zr-trastuzumab-PET/MRI, evaluating the relationship between tumor 89Zr-trastuzumab uptake and in vitro positivity of HER2, assessing the relationship between 89Zr-trastuzumab uptake and response to HER2 therapy.

Sponsor:

University of Alabama at Birmingham

Contacts:

Denise Jeffers, PharmD

charlottejeffers@uabmc.edu

205-975-6469

Sebastian Eady, BS

smeady@uabmc.edu

2059962636

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468